18472-03-2

Basic information

• Product Name: TIMTEC-BB SBB006414
• Synonyms: TIMTEC-BB SBB006414;5-CHLORO-7-NITRO-8-QUINOLINOL;5-chloro-7-nitroquinolin-8-ol
• CAS NO: 18472-03-2
• Molecular Formula: C₉H₅ClN₂O₃
• Molecular Weight: 224.6
• Mol File: 18472-03-2.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 371.9°C at 760 mmHg
• Flash Point: 178.7°C
• Appearance: /
• Density: 1.615g/cm³
• Vapor Pressure: 4.67E-06mmHg at 25°C
• Refractive Index: 1.73
• CAS DataBase Reference: TIMTEC-BB SBB006414(CAS DataBase Reference)
• NIST Chemistry Reference: TIMTEC-BB SBB006414(18472-03-2)
• EPA Substance Registry System: TIMTEC-BB SBB006414(18472-03-2)

Safety Data

• Hazardous Substances Data: 18472-03-2(Hazardous Substances Data)

Usage

InChI:InChI=1/C9H5ClN2O3/c10-6-4-7(12(14)15)9(13)8-5(6)2-1-3-11-8/h1-4,13H

Upstream product

• 95-85-2 2-hydroxy-5-chloro-aniline 
• 130-16-5 5-Chloro-8-hydroxyquinoline 

Downstream Products

• 940298-42-0 tert-butyl 5-chloro-7-[3-(phenylpyridin-2-ylmethyl)ureido]quinolin-8-yloxycarboxylate 
• 940298-38-4 N-(5-chloro-8-hydroxyquinolin-7-yl)-3,3-diphenylpropionamide 
• 1432063-19-8 N-(5,8-dioxo-2-(4-(trifluoromethyl)phenyl)-5,8-dihydroquinolin-7-yl)acetamide 
• 1432063-30-3 7-amino-2-(4-(trifluoromethyl)phenyl)quinoline-5,8-dione 
• 97000-09-4 5-Chloro-2-oxo-oxazolo[4,5-h]quinoline-3-carboxylic acid 2-methoxy-phenyl ester 
• 97000-10-7 5-Chloro-3-[(E)-(3-phenyl-acryloyl)]-3H-oxazolo[4,5-h]quinolin-2-one 
• 86048-40-0 methyl 5-chloroxazolo <4,5-h> quinoline-2-carboxylate 
• 97000-17-4 5-Chloro-2-phenyl-oxazolo[4,5-h]quinoline 
• 18471-93-7 7-amino-5-chloro-8-hydroxyquinoline 
• 18472-06-5 7-amino-8-hydroxyquinoline 
• 1262633-18-0 N-(8-hydroxyquinolin-7-yl)-[1,1'-biphenyl]-4-sulfonamide 
• 1262633-16-8 4-fluoro-N-(8-hydroxyquinolin-7-yl)benzenesulfonamide 
• 1262633-14-6 N-(8-hydroxyquinolin-7-yl)benzenesulfonamide 

Relevant articles and documents

Method of preparing Quinoline-5,8-dione derivatives for TGase 2 inhibitor

I Is -5,8- of the quinoline, dione derivative compound. of Formula I, or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein the compound of Formula, TGase 2 has, inhibitory effects TGase 2, and thus the pharmaceutical composition may be useful for preventing or treating disorders or diseases mediated by TGase 2 or inhibiting. (by machine translation)

Study on Relationship Between Fluorescence Properties and Structure of Substituted 8-Hydroxyquinoline Zinc Complexes

Organic light-emitting diodes (OLEDs) produced from 8-hydroxyquinoline metal complexes play a vital role in modern electroluminescent devices. In this manuscript, a series of 8-hydroxyquinoline derivatives were synthesized by different methods and their corresponding zinc metal complexes were prepared. The UV and fluorescence properties of the complexes were measured aiming to understand the effect of substituents at the quinoline ring on the fluorescence properties of the complexes. When the C-5 of 8-hydroxyquinoline was replaced by halogen group, the fluorescence emission wavelengths had been red-shifted, at the same time, blue-shifted of fluorescence emission wavelength was observed when the C-5 position of 8-hydroxyquinoline was substituted by electron-withdrawing group. When the C-4 position of 8-hydroxyquinolie was substituted by methyl or the C-5 position was substituted by sulfonic acid group, the corresponding zinc complexes had higher fluorescence intensity than 8-hydroxyquinolie zinc.

Substituted oxines inhibit endothelial cell proliferation and angiogenesis

Two substituted oxines, nitroxoline (5) and 5-chloroquinolin-8-yl phenylcarbamate (22), were identified as hits in a high-throughput screen aimed at finding new anti-angiogenic agents. In a previous study, we have elucidated the molecular mechanism of antiproliferative activity of nitroxoline in endothelial cells, which comprises of a dual inhibition of type 2 human methionine aminopeptidase (MetAP2) and sirtuin 1 (SIRT1). Structure-activity relationship study (SAR) of nitroxoline offered many surprises where minor modifications yielded oxine derivatives with increased potency against human umbilical vein endothelial cells (HUVEC), but with entirely different as yet unknown mechanisms. For example, 5-nitrosoquinolin-8-ol (33) inhibited HUVEC growth with sub-micromolar IC50, but did not affect MetAP2 or MetAP1, and it only showed weak inhibition against SIRT1. Other sub-micromolar inhibitors were derivatives of 5-aminoquinolin-8-ol (34) and 8-sulfonamidoquinoline (32). A sulfamate derivative of nitroxoline (48) was found to be more potent than nitroxoline with the retention of activities against MetAP2 and SIRT1. The bioactivity of the second hit, micromolar HUVEC and MetAP2 inhibitor carbamate 22 was improved further with an SAR study culminating in carbamate 24 which is a nanomolar inhibitor of HUVEC and MetAP2. The Royal Society of Chemistry 2012.